

## Antibiogram Data from 2024 Isolates

Niaz Banaei, M.D., Director of Clinical Microbiology Laboratory  
William Rotunno, CLS, Laboratory Reference Technologist, Antibiotics  
Farnaz Foughi, CLS, Laboratory Reference Technologist, AFB  
Laleh Ghafghaichi, CLS, Laboratory Reference Technologist, Mycology

Values expressed are % susceptible R = intrinsic resistance “-” = data not available

Gram Negative Rods	No. of Isolates (a)	Penicillins		Cephalosporins and Lactams					Carbapenems		Aminoglyc's			Others		Urines Only	
		Ampicillin (\$)	Piper/Tazobactam (\$\$)	Cefuroxime (IV) (\$)	Ceftriaxone (\$)	Ceftazidime (\$)	Cefepime (b) (\$)	Aztreonam (\$\$\$)	Ertapenem (\$\$\$)	Meropenem (\$\$)	Amikacin (\$\$\$)	Gentamicin (\$\$\$)	Tobramycin (\$\$\$)	Ciprofloxacin (\$)	Trimethoprim/sulfa (\$)	Cefazolin (c) (\$)	Predicts 1st gen cephem
<i>Achromobacter xylosoxidans</i>	22(d,e)	R	82	R	R	77	0	0	R	96	18	5	14	18	100	R	-
<i>Acinetobacter baumannii</i> complex	14(d,e)	R	-	R	R	79	71	R	R	86	79	71	71	86	86	R	-
<i>Citrobacter freundii</i> complex	26(d,e)	R	61	R	58	61	-	-	100	100	100	100	100	96	92	R	100
<i>Enterobacter cloacae</i> complex	53	R	59	R	51	56	72 / 24	60	81	100	100	100	100	88	90	R	50
<i>Escherichia coli</i>	520	46	94	64	87	95	77 / 7	71	99	99	98	89	89	79	68	81	97
<i>Klebsiella aerogenes</i>	26(d)	R	71	R	61	65	62 / 0	62	77	85	91	100	100	96	79	R	8
<i>Klebsiella oxytoca</i>	45	R	91	69	87	91	79 / 0	79	100	100	100	98	98	98	84	59	97
<i>Klebsiella pneumoniae</i>	100	R	89	85	84	92	85 / 0	95	100	100	99	91	89	82	73	85	21
<i>Morganella morganii</i>	13(d)	R	-	R	85	77	100 / 0	-	100	-	-	77	69	69	69	R	R
<i>Proteus mirabilis</i>	43	84	100	-	95	98	-	100	100	100	100	95	95	91	84	88	R
<i>Pseudomonas aeruginosa</i>	126	R	91	C/T 99		94	93	82	R	94	100(c)	-	100	90	R	R	R
<i>Pseudomonas aeruginosa</i> (CF-mucoid) (f)	26(d,e)	R	92	C/T 92		92	85	76	Imp 84	89	-	-	89	65	R	R	R
<i>Pseudomonas aeruginosa</i> (CF-non-mucoid) (f)	27(d)	R	89	C/T 100		96	96	93	Imp 89	93	-	-	85	93	R	R	R
<i>Salmonella</i> spp.	28(d)	86	-	R	96	-	-	-	-	-	R	R	R	39	86	R	-
<i>Serratia marcescens</i>	37	R	100	R	92	97	100 / 0	100	100	100	100	100	87	95	100	R	R
<i>Stenotrophomonas maltophilia</i>	53	R	R	R	R	-	-	R	R	R	R	R	Levo 93	98	R	-	

- (a) First isolate from each patient was included.
- (b) Shows susceptible / susceptible-dose dependent. Not routinely tested on urine and blood Enterobacterales isolates.
- (c) Urine only.
- (d) Data from isolate totals <30 may be statistically unreliable.
- (e) Includes isolates from 2023.
- (f) Cystic fibrosis patient isolates tested by disk diffusion.

A/S = Ampicillin/Sulbactam; C/T = Ceftolozane/Tazobactam;  
Imp = Imipenem; Levo = Levofloxacin

Values expressed are % susceptible R = intrinsic resistance "-" = data not available

## Gram Positive Cocci

	Number of Isolates (a)	Beta-Lactams							Others										
		Oxacillin/Nafcillin (\$)		Penicillin or Ampicillin (\$)			1st Generation cephem (\$)	Cefuroxime (\$)	Ceftriaxone (\$)	Meropenem (\$\$\$)	Levofloxacin (\$)	Ciprofloxacin (b) (\$)	Clindamycin (c) (\$)	Erythromycin (\$\$\$)	Nitrofurantoin (b) (\$\$\$)	Trimethoprim/sulfa (\$)	Vancomycin (\$\$\$)	Tetracycline (\$\$)	Linezolid (\$\$\$)
		%S	%I	%R															
Staphylococcus aureus	485	86	(d)	-	-	86	-	-	-	-	-	78	70	-	100	100	-	-	
MRSA only	65	0	0	-	-	0	-	-	-	-	-	62	26	-	100	100	89	100	
Staphylococcus lugdunensis	4(e)	100	(d)	-	-	100	-	-	-	-	-	75	100	-	100	100	-	-	
Staphylococcus spp., Coagulase-negative	53	28	(d)	-	-	28	-	-	-	-	-	58	29	-	64	100	-	-	
Enterococcus faecium	13(e)	-	46	-	54	R	R	R	-	-	50	R	-	29	R	100	-	100	
Enterococcus faecalis	26(e)	-	100	-	0	R	R	R	-	-	-	R	-	-	R	100	-	-	
Streptococcus group B	22	-	100	0	0	-	-	-	-	-	-	41	-	-	-	-	-	-	
Viridans group Streptococci	33	-	70	16	11	-	-	97	-	85	-	79	49	-	-	100	-	-	
Streptococcus pneumoniae	26(e)	-	65(f)	-	35	-	92	96(g)	92	-	-	81	73	-	65	100	Doxycycline 67	-	

**Drug cost:** Please choose the appropriate antibiotic based on best spectrum of coverage and lowest cost. Costs are reflective of 1 day of therapy based on adult dosing and include drug levels and reformulations.

\$ = \$0-20  
 \$\$ = \$20-50  
 \$\$\$ = \$50-100  
 \$\$\$\$ = >\$100

(a) First isolate from each patient was included. (b) Urine only. (c) Testing for inducible clindamycin resistance performed on all Staphylococci, group B Strep, and S. pneumoniae. (d) Penicillin sensitivity confirmed by request. (e) Data from isolate totals <30 may be statistically unreliable. (f) Based on meningitis interpretive criteria (more conservative). Nonmeningitis interpretation is 96%. (g) Ceftriaxone uses the meningitis interpretive criteria (more conservative).

## Candida

Percent Susceptible By Broth Microdilution (YeastOne, Trek Diagnostics)	No. Tested	Amphotericin B (a) (\$\$\$)	Fluconazole (b) (\$)	Voriconazole (\$\$\$)	Caspofungin (c) (\$\$\$)
Candida albicans	17(d,e)	100	100/0	100	94
Candida glabrata	6(d,e)	100	0/100	-	100
Candida parapsilosis	14(d,e)	100	100/0	100	100
Other Candida species	4(d,e)	100	(f)	75	50

## Haemophilus influenzae

For infections with beta-lactamase producing H. influenzae: cefuroxime, ceftriaxone, trimethoprim/sulfamethoxazole, amoxicillin/clavulanate, or azithromycin is recommended.  
 Ceftriaxone is drug of choice for CNS infections.  
 At LPCH, 63% (n=30) of H. influenzae are ampicillin susceptible.

(a) Suggested Ampho Resistant breakpoint MIC > or = 2 mcg/ml. (b) Shows susceptible / susceptible-dose dependent.  
 (c) Consult Peds ID if Caspofungin being considered for treatment. (d) Data from isolate totals <30 may be statistically unreliable.  
 (e) Includes isolates from 2023. (f) Species other than C. krusei are 100% susceptible; C. krusei is intrinsically resistant to fluconazole.